Electroneurophysiological criteria of efficiency of pathogenetic therapy in diabetic polyneuropathy.
Электронейрофизиологические критерии эффективности патогенетической терапии диабетической полинейропатии.
Lubov Kuzina 1, Gulnaz Kaishibayeva 2
More Detail
1 Department of myasthenia and demyelinating diseases, SPC “Institute of Neurology named by Smagul Kaishibayev”, Almaty, Kazakhstan
2 Department of neurology, JSC “Kazakh Medical University of Continuing Education”, Almaty, Kazakhstan
OPEN ACCESS
2882 Views
2044 Downloads
ABSTRACT
Purpose: to estimate efficiency of pathogenetic therapy of diabetic polyneuropathy with including of benfotiaminby means of an electroneuromyography.
Materials: assessment of efficiency of pathogenetic therapy of diabetic polyneuropathy with including of benfotiaminat patients with various experience of a diabetes mellitus 2 types was carried out. The research included three groups of patients with an experience of diabetes 2 type – 1-3 years (1 group), 3-7 years (the 2nd group), 7-10 years (the 3rd group). The conduction research on nerves of the lower extremities by an electroneuromyography method was the main criterion of efficiency (primary final point).
Results: according to ENMG-control statistically significant improvement of conduction on peripheric nerves against the background of therapy by benfotiamin within 12 weeks was shown. More faster improvement of conduction was reached in groups with a smaller experience of a diabetes mellitus (up to 7 years) and at the patients who were earlier receiving courses of pathogenetic therapy.
Conclusions: Including of benfotiamin in a complex of therapy of diabetic polyneuropathy allows to achieve reliable improvement of a condition of peripheric nerves from patients with various experience of a diabetes mellitus 2 types.
REFERENCES
- Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. The Lancet Neurology. 2012 Jun 30;11(6):521-34.
- Zinoveva O.E. Rol neyrotropnyih vitaminov v patogeneticheskoy terapii diabeticheskoy nevropatii. Consilium Medicum. 2009, 12; 43-47.
- Umerova A.R., Dorfman I.P., Orlova E.A. Sovremennyie podhodyi k lecheniyu diabeticheskoy polineyropatii. Rossiyskiy Meditsinskiy Zhurnal. 2015, 26;1538-1542.
- Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes care. 2010 Oct 1;33(10):2285-93.
- Stracke H, Lindemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Experimental and clinical endocrinology & diabetes. 1996;104(04):311-6.
- McCann VJ, Davis RE. Pyridoxine and diabetic neuropathy: a double-blind controlled study. Diabetes Care. 1983 Jan 1;6(1):102-3.
- Ledermann H, Widey KD. Behandlung der manifesten diabetichen polyneuropathie. Therapiewoche. 1989;39:1445-9.
- Doppelblinde HE. placebokontrollierte Untersuchung zur klinischen Wirksamkeit und Verträglichkeit von Benfotiamin Ankermann Dragees bei diabetischen Polyneuropathien. Kongreβbericht. 1995. Internist.;36(2)-7.
- Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature medicine. 2003 Mar 1;9(3):294-9.
- Levin O.S. Diabeticheskaya polinevropatiya: sovremennyie podhodyi k diagnostike i patogeneticheskoy terapii. Klinitsist. 2013; 2:54-62.
- Zabelina V. D. Diabeticheskaya neyropatiya – problema kachestva zhizni bolnyih saharnyim diabetom. Consilium Medicum. 2011;13(12):40–45.
- Kayshibaev N.S., Kuzina L.A. Elektroneyromiograficheskie kriterii ranney diagnostiki i monitoring medikamentoznoy korrektsii subklinicheskih i klinicheskih proyavleniy polineyropatii u patsientov s vpervyie ustanovlennyim diagnozom “Saharnyiy diabet 2 tipa”. Metodicheskie rekomendatsii. OO “ Liga nevrologov - Nauchno-prakticheskiy tsentr “Institut nevrologii imeni Smagula Kayshibaeva”. Almatyi, 2012. pp44.
- Shprah V. V., Tirikov I.V., Mihalevich I.M. Faktoryi riska i sposob prognozirovaniya razvitiya polineyropatii u bolnyih saharnyim diabetom 2 tipa. Sibirskiy meditsinskiy zhurnal. 2012;108(1):65–67.
- Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF. The Effects of Long-Term Oral Benfotiamine Supplementation on Peripheral Nerve Function and Inflammatory Markers in Patients with Type 1 Diabetes. Diabetes Care. 2012 May 1;35(5):1095-7.